As researchers learn more about the pathogenesis of rosacea, they can better understand the benefits of certain medications and find opportunities for new therapies.
In the search for rosacea treatments, topical ivermectin 1 percent cream met its safety endpoints in two pivotal trials that included a total of 910 actively treated subjects, Galderma announced at the 72nd Annual Meeting of the American Academy of Dermatology.
A study shows data to suggest there is evidence of subtype progression in rosacea, and that flushing is not a universal characteristic of patients with subtype 1 rosacea.
Although the symptoms of acne and rosacea are well established, clear and definitive etiologies of these conditions have largely been unknown. Recent research, however, has shed new light into the pathophysiology of these conditions, paving the way for more targeted therapies.
The treatment of rosacea is becoming increasingly patient-friendly, according to an expert.